The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 352:1039-1041 March 10, 2005 Number 10
NextNext

Implantable Cardioverter–Defibrillator Therapy after Myocardial Infarction

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Hohnloser, S. H.
-PubMed Citation
To the Editor: Hohnloser et al. (Dec. 9 issue),1 who conducted the Defibrillator in Acute Myocardial Infarction Trial (DINAMIT), assume that implantable cardioverter–defibrillator (ICD) therapy early after myocardial infarction decreases the rate of death due to arrhythmia but that the patients die of other cardiac disease. We believe alternatives must be considered.

First, it should not be assumed that the mechanism of death has been changed by the ICD; rather, the presence of an ICD will affect classification (a doctor or committee member will be less likely to believe a death is due to arrhythmia if a patient has a . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.